Skip to main content

Table 1 Patients’ characteristics

From: A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment

  n (%) or median (mean +/− SD)  
Variables ABI (n:188) ENZ(n:261) p value
Age
  > 75.6 years 105 (55.9%) 120 (46.0%) 0.039
  ≤ 75.6 years 83 (44.1%9 141 (54.0%)
Initial distant Metastasis
 Yes 87 (46.3%) 157 (60.2%) 0.248
 No 65 (34.6%) 99 (37.9%)
 Unknown 36 (19.1%) 5 (1.9%)
 Initial PSA (ng/mL) 110 (616.2 +/−  1467.7) 100 (648.1 +/−  1534.9) < 0.001
Gleason Score
  ≥ 8 93 (49.5%) 121 (46.4%) 0.515
  < 8 95 (50.5%) 140 (53.6%)
 Pre ABI/ENZ PSA (ng/mL) 26.0 (189.8 +/−  595.6) 38.8 (233.3 +/−  737.5) < 0.001
Pre DOC Treatment
 Yes 61 (32.4%) 145 (55.6%) < 0.001
 No 127 (67.6%) 116 (44.4%)
ALP
  > 274 IU/L 92 (48.9%) 119 (45.6%) 0.484
  ≤ 274 IU/L 96 (51.1%) 142 (54.4%)
LDH
  > 220 IU/L 96 (51.1%) 122 (46.7%) 0.366
  ≤ 220 IU/L 92 (48.9%) 139 (53.3%)
  1. PSA Prostate-specific antigen, CRPC Castration-resistant prostate cancer, DOC Docetaxel
  2. ABI Abiraterone, ENZ Enzalutamide, ALP Alkaline phosphatase, LDH Lactate dehydrogenase